FATE Fate Therapeutics, Inc.
Healthcare$2.15-4.44%ClosedMarket Cap: $250.6M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.50
P/S
41.52
EV/EBITDA
-2.46
DCF Value
$-0.46
FCF Yield
-41.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
53.8%
Operating Margin
-2207.5%
Net Margin
-2056.8%
ROE
-58.9%
ROA
-45.6%
ROIC
-53.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $1.3M | -124.6% | $-33.0M | $-31.2M | $— | — |
| Q4 null | $1.4M | 100.0% | $-34.7M | $-32.4M | $— | — |
| FY null | $6.6M | -94.1% | $-147.7M | $-136.3M | $— | — |
| Q3 null | $1.7M | 100.0% | $-34.7M | $-32.3M | $— | — |
| Q2 null | $1.9M | 100.0% | $-37.0M | $-34.1M | $— | — |
| Q1 null | $1.6M | 100.0% | $-41.3M | $-37.6M | $— | — |
| Q4 null | $1.9M | 100.0% | $-61.7M | $-52.2M | $— | — |
| FY null | $13.6M | 100.0% | $-210.3M | $-186.3M | $— | — |
| Q3 null | $3.1M | 100.0% | $-52.4M | $-47.7M | $— | — |
| Q2 null | $6.8M | 30.3% | $-45.1M | $-38.4M | $— | — |
| Q1 null | $1.9M | -150.4% | $-51.1M | $-48.0M | $— | — |
| Q4 2023 | $1.7M | -191.5% | $-48.1M | $-44.1M | $-0.45 | — |